Andrew F. Shorr, MD, MPH, MBA, FACP, FCCP - Improving the Diagnosis, Treatment, and Outcomes of Patients With HAP and VAP: A Critical Look at Current Guidelines and New Treatment Options

37:09
 
Share
 

Manage episode 245033256 series 103624
By PeerView Press, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
Go online to PeerView.com/GBE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in pulmonary and critical care medicine discusses the microbiology, diagnosis, and treatment of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). Upon completion of this activity, participants will be able to: List the pathogens commonly implicated in causing hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), Identify risk factors for multidrug-resistant HAP and VAP, Employ an evidence-based approach to readily diagnose HAP and VAP in the critical care setting, Select empiric therapy for HAP and VAP based on the local distribution of pathogens and their antimicrobial susceptibilities, as well as individual patients’ risk factors for multidrug resistance and prior microbiology data, Summarize key features and critical differences between novel antibiotics for the treatment of HAP and VAP, Optimize antibiotic selection and use (eg, dosing) in individual patients with HAP or VAP, considering current evidence and expert recommendations as well as the appropriate use of new and emerging agents

171 episodes